<DOC>
	<DOCNO>NCT02798679</DOCNO>
	<brief_summary>The purpose study determine whether pre-existing cardiac fibrosis predictor cancer treatment-related cardiotoxicity .</brief_summary>
	<brief_title>Cardiac Fibrosis Risk Prediction Cancer Treatment-Related Cardiotoxicity</brief_title>
	<detailed_description />
	<mesh_term>Cardiotoxicity</mesh_term>
	<criteria>Stage IIII breast cancer lymphoma &gt; 2 year life expectancy A treatment plan include anthracyclines and/or trastuzumab Age &gt; 45 year Able hold breath 10 second Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Refusal inability provide inform consent Known heart failure LVEF &lt; 50 % Heart rate 100 bpm Renal dysfunction GFR &lt; 30 mL/min/1.73m2 Participants pacemaker , defibrillator , function neurostimulator device implant electronic device Symptomatic claustrophobia Plans move within 24 month enrollment</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>